These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 34000224)

  • 21. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.
    FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M
    Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Patel N; Ansar M; Pham A; Thomsen K; McKinzie CJ; Polineni D; Esther CR; Brown RF
    Pediatr Pulmonol; 2024 Apr; 59(4):863-866. PubMed ID: 38179880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
    Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
    Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
    J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
    [No Abstract]   [Full Text] [Related]  

  • 25. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in Lung Function after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Do Not Forget Anatomy!
    Martin C; Regard L; Chassagnon G; Burgel PR
    Am J Respir Crit Care Med; 2022 Jun; 205(11):1365-1366. PubMed ID: 35358030
    [No Abstract]   [Full Text] [Related]  

  • 29. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
    Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
    J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.
    Causer AJ; Shute JK; Cummings MH; Shepherd AI; Wallbanks SR; Pulsford RM; Bright V; Connett G; Saynor ZL
    Pediatr Pulmonol; 2022 Nov; 57(11):2652-2658. PubMed ID: 35851858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
    J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
    Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
    Martin C; Reynaud-Gaubert M; Hamidfar R; Durieu I; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Lemonnier L; Burnet E; Paillasseur JL; Da Silva J; Burgel PR
    J Cyst Fibros; 2022 May; 21(3):489-496. PubMed ID: 35123901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor.
    McParland C; Nunn M; Marras TK; Chiasson M
    J Cyst Fibros; 2024 Jan; 23(1):38-40. PubMed ID: 37076409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.
    Shaughnessy CA; Zeitlin PL; Bratcher PE
    J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis.
    Wisniewski BL; Aylward SC; Jordan CO; Kopp BT; Paul GR
    J Cyst Fibros; 2022 May; 21(3):e217-e220. PubMed ID: 35131172
    [No Abstract]   [Full Text] [Related]  

  • 39. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
    Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
    Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
    Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
    Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.